NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 2,647 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 2,647 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $33.25, for a total value of $88,012.75. Following the sale, the chief accounting officer owned 12,353 shares in the company, valued at $410,737.25. This represents a 17.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Louise Frederika Kooij also recently made the following trade(s):

• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.30, for a total value of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $36.21, for a total value of $2,719,986.57.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.68, for a total value of $928,072.48.

NewAmsterdam Pharma Price Performance

NASDAQ NAMS traded up $1.43 during trading hours on Wednesday, reaching $35.45. The company’s stock had a trading volume of 759,782 shares, compared to its average volume of 845,920. The firm has a fifty day simple moving average of $36.87 and a 200-day simple moving average of $29.80. NewAmsterdam Pharma Company N.V. has a 52 week low of $14.06 and a 52 week high of $42.00. The stock has a market cap of $4.02 billion, a P/E ratio of -17.29 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). The company had revenue of $0.35 million during the quarter, compared to analyst estimates of $4.54 million. NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. On average, research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of NAMS. CIBC Bancorp USA Inc. bought a new position in shares of NewAmsterdam Pharma during the 3rd quarter worth about $886,000. Polar Capital Holdings Plc increased its position in NewAmsterdam Pharma by 15.6% in the 3rd quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock valued at $82,807,000 after buying an additional 393,855 shares in the last quarter. HighVista Strategies LLC raised its stake in NewAmsterdam Pharma by 65.1% during the 3rd quarter. HighVista Strategies LLC now owns 31,831 shares of the company’s stock worth $905,000 after buying an additional 12,557 shares during the period. Fred Alger Management LLC boosted its holdings in NewAmsterdam Pharma by 87.2% in the third quarter. Fred Alger Management LLC now owns 41,264 shares of the company’s stock worth $1,174,000 after acquiring an additional 19,227 shares in the last quarter. Finally, Duquesne Family Office LLC grew its stake in NewAmsterdam Pharma by 131.2% in the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after acquiring an additional 1,091,525 shares during the period. 89.89% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on NAMS shares. The Goldman Sachs Group upped their target price on NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a report on Tuesday, December 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Wednesday, October 8th. Citigroup boosted their target price on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. Leerink Partners reiterated an “outperform” rating and set a $55.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday. Finally, HC Wainwright initiated coverage on NewAmsterdam Pharma in a research note on Monday, October 20th. They issued a “buy” rating and a $52.00 price objective on the stock. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.73.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.